‌

US Patent 10407501 Humanized or chimeric CD3 antibodies

Patent 10407501 was granted and assigned to Genmab A/S on September, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Aran Frank Labrijn0

Edward Norbert Van Den Brink0

Isil Altintas0

Joyce Meesters0

Paul Parren0

Rik Rademaker0

Janine Schuurman0

Joost J. Neijssen0

Date of Patent

September 10, 2019

0

Patent Application Number

151104140

Date Filed

January 8, 2015

0

Patent Citations Received

US Patent 11970544 Antibodies

0

US Patent 11535679 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

0

US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

0

US Patent 11008399 Antibodies

0

US Patent 11608383 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

0

US Patent 11261254 Antibodies

0

US Patent 11359015 Humanized or chimeric CD3 antibodies

US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

0

...

Patent Primary Examiner

Zachary S Skelding

0

Patent abstract

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10407501 Humanized or chimeric CD3 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.